BACKGROUND AND METHODS: There is an urgent need for peripheral surrogates of Alzheimer's disease (AD) that accurately reflect disease state and severity as well as correlate with key features of its neuropathology. The aim of this study was to identify plasma proteins associated with known in vivo markers of disease activity. In an earlier proteomic study of plasma, we discovered a panel of 15 proteins that were differentially expressed in AD and further validated complement factor-H (CFH) and alpha-2-macroglobulin (A2M) as AD-specific plasma biomarkers. In the present study, we extended these findings by testing the associations of these plasma proteins with neuro-imaging measures of disease progression in AD. We combined (1)H-magnetic resonance spectroscopy of the hippocampus and MRI-based hippocampal volumetry with proteomic analysis of plasma in early AD and mild cognitive impairment (MCI) to achieve this goal. Using (1)H-magnetic resonance spectroscopy, we derived estimates of the hippocampal metabolite ratio N-acetylaspartate/myo-inositol (NAA/mI), a biochemical measure that is associated with cognitive decline in early AD. We also undertook a proteomic analysis of plasma in these individuals using two-dimensional gel electrophoresis (2DGE). RESULTS: We observed that two plasma proteins previously shown to be differentially expressed in AD, complement factor-H (CFH) and alpha-2-macroglobulin (A2M) showed significant positive correlations with hippocampal NAA/mI ratio in AD. CONCLUSIONS: The association of plasma CFH and A2M with hippocampal NAA/mI in this cohort of AD subjects suggests that these proteins may reflect disease progression in early AD. These findings warrant validation in large population-based datasets.
BACKGROUND AND METHODS: There is an urgent need for peripheral surrogates of Alzheimer's disease (AD) that accurately reflect disease state and severity as well as correlate with key features of its neuropathology. The aim of this study was to identify plasma proteins associated with known in vivo markers of disease activity. In an earlier proteomic study of plasma, we discovered a panel of 15 proteins that were differentially expressed in AD and further validated complement factor-H (CFH) and alpha-2-macroglobulin (A2M) as AD-specific plasma biomarkers. In the present study, we extended these findings by testing the associations of these plasma proteins with neuro-imaging measures of disease progression in AD. We combined (1)H-magnetic resonance spectroscopy of the hippocampus and MRI-based hippocampal volumetry with proteomic analysis of plasma in early AD and mild cognitive impairment (MCI) to achieve this goal. Using (1)H-magnetic resonance spectroscopy, we derived estimates of the hippocampal metabolite ratio N-acetylaspartate/myo-inositol (NAA/mI), a biochemical measure that is associated with cognitive decline in early AD. We also undertook a proteomic analysis of plasma in these individuals using two-dimensional gel electrophoresis (2DGE). RESULTS: We observed that two plasma proteins previously shown to be differentially expressed in AD, complement factor-H (CFH) and alpha-2-macroglobulin (A2M) showed significant positive correlations with hippocampal NAA/mI ratio in AD. CONCLUSIONS: The association of plasma CFH and A2M with hippocampal NAA/mI in this cohort of AD subjects suggests that these proteins may reflect disease progression in early AD. These findings warrant validation in large population-based datasets.
Authors: Richard A Frank; Douglas Galasko; Harald Hampel; John Hardy; Mony J de Leon; Pankaj D Mehta; Joseph Rogers; Eric Siemers; John Q Trojanowski Journal: Neurobiol Aging Date: 2003 Jul-Aug Impact factor: 4.673
Authors: Y Kanoh; N Ohtani; T Mashiko; S Ohtani; T Nishikawa; S Egawa; S Baba; H Ohtani Journal: Anticancer Res Date: 2001 Jan-Feb Impact factor: 2.480
Authors: T van Amelsvoort; E Daly; D Robertson; J Suckling; V Ng; H Critchley; M J Owen; J Henry; K C Murphy; D G Murphy Journal: Br J Psychiatry Date: 2001-05 Impact factor: 9.319
Authors: K Buerger; S J Teipel; R Zinkowski; K Blennow; H Arai; R Engel; K Hofmann-Kiefer; C McCulloch; U Ptok; R Heun; N Andreasen; J DeBernardis; D Kerkman; H- J Moeller; P Davies; H Hampel Journal: Neurology Date: 2002-08-27 Impact factor: 9.910
Authors: N Bahia El Idrissi; S Hakobyan; V Ramaglia; A Geluk; B Paul Morgan; P Kumar Das; F Baas Journal: Clin Exp Immunol Date: 2016-03-31 Impact factor: 4.330
Authors: Matthew Zabel; Matthew Schrag; Claudius Mueller; Weidong Zhou; Andrew Crofton; Floyd Petersen; April Dickson; Wolff M Kirsch Journal: J Alzheimers Dis Date: 2012 Impact factor: 4.472
Authors: V R Varma; S Varma; Y An; T J Hohman; S Seddighi; R Casanova; A Beri; E B Dammer; N T Seyfried; O Pletnikova; A Moghekar; M R Wilson; J J Lah; R J O'Brien; A I Levey; J C Troncoso; M S Albert; M Thambisetty Journal: Mol Psychiatry Date: 2016-11-22 Impact factor: 15.992
Authors: Daniel Martins-de-Souza; Laura W Harris; Paul C Guest; Christoph W Turck; Sabine Bahn Journal: Eur Arch Psychiatry Clin Neurosci Date: 2009-12-09 Impact factor: 5.270